---
title: "Mereo BioPharma Group plc (MREO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MREO.US.md"
symbol: "MREO.US"
name: "Mereo BioPharma Group plc"
industry: "Biotechnology"
datetime: "2026-04-15T16:03:46.022Z"
locales:
  - [en](https://longbridge.com/en/quote/MREO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MREO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MREO.US.md)
---

# Mereo BioPharma Group plc (MREO.US)

## Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.mereobiopharma.com](https://www.mereobiopharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:17.000Z

**Overall: C (0.60)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 178 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | 3.18% |  |
| P/B Ratio | 1.28 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 52513586.69 |  |
| Revenue | 500000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -82.21% | E |
| Profit Margin | -8375.60% | E |
| Gross Margin | 73.40% | A |
| Revenue YoY | 0.00% | C |
| Net Profit YoY | 3.18% | C |
| Total Assets YoY | -39.89% | E |
| Net Assets YoY | -32.89% | E |
| Cash Flow Margin | 73.96% | C |
| OCF YoY | 0.00% | C |
| Turnover | 0.01 | E |
| Gearing Ratio | 10.89% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Mereo BioPharma Group plc",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "3.18%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "52513586.69",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "500000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-82.21%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-8375.60%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "73.40%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "3.18%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-39.89%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-32.89%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "73.96%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.89%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.25 | 209/393 | - | - | - |
| PB | 1.28 | 118/393 | 6.56 | 5.26 | 1.44 |
| PS (TTM) | 105.03 | 263/393 | 623.66 | 550.48 | 124.63 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | C | A |
| 05 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-02T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 50% |
| Overweight | 1 | 13% |
| Hold | 3 | 38% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.31 |
| Highest Target | 3.01 |
| Lowest Target | 0.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MREO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MREO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MREO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MREO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**